Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in PLoS Med

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    July 2019
  1. SCHUTZ C, Barr D, Andrade BB, Shey M, et al
    Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study.
    PLoS Med. 2019;16:e1002840.
    PubMed     Text format     Abstract available


  2. DOOLEY KE, Hanna D, Mave V, Eisenach K, et al
    Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
    PLoS Med. 2019;16:e1002842.
    PubMed     Text format    


  3. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002880.
    PubMed     Text format     Abstract available


  4. OLLIARO PL, Vaillant M
    Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.
    PLoS Med. 2019;16:e1002850.
    PubMed     Text format     Abstract available


  5. DAVIES G, Boeree M, Hermann D, Hoelscher M, et al
    Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
    PLoS Med. 2019;16:e1002851.
    PubMed     Text format     Abstract available


    June 2019
  6. CAMPBELL JR, Dowdy D, Schwartzman K
    Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries.
    PLoS Med. 2019;16:e1002824.
    PubMed     Text format     Abstract available



  7. Correction: Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002823.
    PubMed     Text format     Abstract available


    May 2019
  8. LALVANI A, Berrocal-Almanza LC, Halliday A
    Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination.
    PLoS Med. 2019;16:e1002814.
    PubMed     Text format     Abstract available


  9. KLEIN K, Bernachea MP, Iribarren S, Gibbons L, et al
    Correction: Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002826.
    PubMed     Text format     Abstract available


    April 2019
  10. GUPTA-WRIGHT A, Corbett EL, Wilson D, van Oosterhout JJ, et al
    Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study.
    PLoS Med. 2019;16:e1002776.
    PubMed     Text format     Abstract available


  11. STRYDOM N, Gupta SV, Fox WS, Via LE, et al
    Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    PLoS Med. 2019;16:e1002773.
    PubMed     Text format     Abstract available


  12. KAWASAKI M, Echiverri C, Raymond L, Cadena E, et al
    Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    PLoS Med. 2019;16:e1002780.
    PubMed     Text format     Abstract available


  13. PENN-NICHOLSON A, Hraha T, Thompson EG, Sterling D, et al
    Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    PLoS Med. 2019;16:e1002781.
    PubMed     Text format     Abstract available


  14. CHURCHYARD GJ, Swindells S
    Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB.
    PLoS Med. 2019;16:e1002787.
    PubMed     Text format     Abstract available


  15. WARSINSKE H, Vashisht R, Khatri P
    Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.
    PLoS Med. 2019;16:e1002786.
    PubMed     Text format     Abstract available


  16. VEKEMANS J, O'Brien KL, Farrar J
    Tuberculosis vaccines: Rising opportunities.
    PLoS Med. 2019;16:e1002791.
    PubMed     Text format     Abstract available


  17. MANJALY THOMAS ZR, Satti I, Marshall JL, Harris SA, et al
    Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    PLoS Med. 2019;16:e1002790.
    PubMed     Text format     Abstract available


  18. COLMAN RE, Mace A, Seifert M, Hetzel J, et al
    Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    PLoS Med. 2019;16:e1002794.
    PubMed     Text format     Abstract available


  19. KLEIN K, Bernachea MP, Irribarren S, Gibbons L, et al
    Evaluation of a social protection policy on tuberculosis treatment outcomes: A prospective cohort study.
    PLoS Med. 2019;16:e1002788.
    PubMed     Text format     Abstract available


  20. GARCIA-PRATS AJ, Schaaf HS, Draper HR, Garcia-Cremades M, et al
    Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    PLoS Med. 2019;16:e1002789.
    PubMed     Text format     Abstract available


  21. HATHERILL M, Chaisson RE, Denkinger CM
    Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies.
    PLoS Med. 2019;16:e1002795.
    PubMed     Text format     Abstract available


    March 2019
  22. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Correction: Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002764.
    PubMed     Text format     Abstract available


  23. PHILLIPS PPJ, Mitnick CD, Neaton JD, Nahid P, et al
    Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
    PLoS Med. 2019;16:e1002767.
    PubMed     Text format     Abstract available


    February 2019
  24. SUBBARAMAN R, Nathavitharana RR, Mayer KH, Satyanarayana S, et al
    Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.
    PLoS Med. 2019;16:e1002754.
    PubMed     Text format     Abstract available


    January 2019
  25. MABUD TS, de Lourdes Delgado Alves M, Ko AI, Basu S, et al
    Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil.
    PLoS Med. 2019;16:e1002737.
    PubMed     Text format     Abstract available


    September 2018
  26. SUTHAR AB, Moonan PK, Alexander HL
    Towards national systems for continuous surveillance of antimicrobial resistance: Lessons from tuberculosis.
    PLoS Med. 2018;15:e1002658.
    PubMed     Text format     Abstract available


  27. KWAN A, Daniels B, Saria V, Satyanarayana S, et al
    Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities.
    PLoS Med. 2018;15:e1002653.
    PubMed     Text format     Abstract available


    August 2018
  28. MCINTOSH AI, Jenkins HE, White LF, Barnard M, et al
    Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
    PLoS Med. 2018;15:e1002638.
    PubMed     Text format     Abstract available


    July 2018
  29. ALIPANAH N, Jarlsberg L, Miller C, Linh NN, et al
    Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
    PLoS Med. 2018;15:e1002595.
    PubMed     Text format     Abstract available


  30. HARAUSZ EP, Garcia-Prats AJ, Law S, Schaaf HS, et al
    Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    PLoS Med. 2018;15:e1002591.
    PubMed     Text format     Abstract available


    June 2018
  31. COLDIRON ME, Assao B, Page AL, Hitchings MDT, et al
    Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.
    PLoS Med. 2018;15:e1002593.
    PubMed     Text format     Abstract available


    March 2018
  32. PAI M
    Time for high-burden countries to lead the tuberculosis research agenda.
    PLoS Med. 2018;15:e1002544.
    PubMed     Text format     Abstract available


    January 2018
  33. DAVIES B, Turner KME, Benfield T, Frolund M, et al
    Pelvic inflammatory disease risk following negative results from chlamydia nucleic acid amplification tests (NAATs) versus non-NAATs in Denmark: A retrospective cohort.
    PLoS Med. 2018;15:e1002483.
    PubMed     Text format     Abstract available


    December 2017
  34. KENDALL EA, Schumacher SG, Denkinger CM, Dowdy DW, et al
    Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
    PLoS Med. 2017;14:e1002472.
    PubMed     Text format     Abstract available


    November 2017
  35. RUDGARD WE, Evans CA, Sweeney S, Wingfield T, et al
    Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.
    PLoS Med. 2017;14:e1002418.
    PubMed     Text format     Abstract available


  36. SHETE PB, Dowdy DW
    Measuring success: The challenge of social protection in helping eliminate tuberculosis.
    PLoS Med. 2017;14:e1002419.
    PubMed     Text format     Abstract available


  37. YATES TA, Tomlinson LA, Bhaskaran K, Langan S, et al
    Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.
    PLoS Med. 2017;14:e1002457.
    PubMed     Text format     Abstract available


    October 2017
  38. DATTA S, Saunders MJ, Tovar MA, Evans CA, et al
    Improving tuberculosis diagnosis: Better tests or better healthcare?
    PLoS Med. 2017;14:e1002406.
    PubMed     Text format     Abstract available


  39. SYLVIA S, Xue H, Zhou C, Shi Y, et al
    Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study.
    PLoS Med. 2017;14:e1002405.
    PubMed     Text format     Abstract available


  40. KEITEL K, Kagoro F, Samaka J, Masimba J, et al
    A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial.
    PLoS Med. 2017;14:e1002411.
    PubMed     Text format     Abstract available


  41. WHITTLES LK, White PJ, Didelot X
    Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: A modelling study.
    PLoS Med. 2017;14:e1002416.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: